Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
70.47 USD
0.47%
Market Closed
Updated:
Apr 28, 2024
Prestige Consumer Healthcare Inc
Cost of Revenue
|
Prestige Consumer Healthcare Inc
Cost of Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Cost of Revenue
-$507.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$24.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$10.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$17.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$15.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$7.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is Prestige Consumer Healthcare Inc's Cost of Revenue?
Cost of Revenue
-507.8m
USD
-507.8m
USD
Based on the financial report for Dec 31, 2023, Prestige Consumer Healthcare Inc's Cost of Revenue amounts to -507.8m USD.
What is Prestige Consumer Healthcare Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
-7%
Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for Prestige Consumer Healthcare Inc have been -8% over the past three years , -3% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
